Tech Company Financing Transactions
4Tissue Funding Round
On 10/22/2026, 4Tissue secured $7.8 million in Series A funding from private investors.
Transaction Overview
Company Name
Announced On
10/22/2026
Transaction Type
Venture Equity
Amount
$7,800,000
Round
Series A
Investors
Proceeds Purpose
The financing will support 4Tissue's next phase of development, focusing on its first-in-human (FIH) study, manufacturing scale-up and further development of its technology platform for additional applications in regenerative medicine.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Technologiepark 48
Zwijnaarde, B-9052
Belgium
Zwijnaarde, B-9052
Belgium
Phone
Undisclosed
Website
Email Address
Overview
4Tissue is a biotech company at the forefront of regenerative medicine, utilizing advanced bio-interactive hydrogels to transition from cells to tissue engineering. Founded through a collaboration between Prof. Phillip Blondeel, a global leader in plastic and reconstructive surgery, and Prof. Dr. Sandra Van Vlierberghe, an expert in polymer chemistry, 4Tissue is a spin-off from Ghent University (UGent), Ghent University Hospital (UZGent), and the Vrije Universiteit Brussel (VUB).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Benoit Moreaux
Browse more venture capital transactions:
Prev: 10/22/2026: Whop venture capital transaction
Next: 10/22/2026: Different venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC transactions reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs